Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronjon Chakraverty

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
JACC. Cardiooncology|September 6, 2024
Predictive Performance of Cardiovascular Risk Scores in Cancer Survivors From the UK BiobankCeleste McCracken, Dorina-Gabriela Condurache, Liliana Szabo, et al.
Blood|October 2, 2013
Cell-intrinsic regulation of murine dendritic cell function and survival by prereceptor amplification of glucocorticoidAnnelise Soulier, Sandra M Blois, Shivajanani Sivakumaran, et al.
The Lancet. Oncology|October 3, 2024
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignanciesForam Khatsuria, Christel McMullan, Olalekan Lee Aiyegbusi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 19, 2014
OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescenceSarah Buchan, Teresa Manzo, Barry Flutter, et al.
Blood|April 8, 2010
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioningAdam J Mead, Kirsty J Thomson, Emma C Morris, et al.
Journal of Patient-Reported Outcomes|March 24, 2026
The PRO-CAR-T™ study: achieving excellence in patient and public involvement and engagementKaren L Shaw, Sarah E Hughes, Olalekan L Aiyegbusi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphomaKirsty J Thomson, Emma C Morris, Don Milligan, et al.
The Journal of Experimental Medicine|August 3, 2005
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramersMark Cobbold, Naeem Khan, Batoul Pourgheysari, et al.
The New England Journal of Medicine|July 14, 2021
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host DiseaseRobert Zeiser, Nicola Polverelli, Ron Ram, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 StudyRobert Zeiser, Domenico Russo, Ron Ram, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
JACC. Cardiooncology|September 6, 2024
Predictive Performance of Cardiovascular Risk Scores in Cancer Survivors From the UK BiobankCeleste McCracken, Dorina-Gabriela Condurache, Liliana Szabo, et al.
Blood|October 2, 2013
Cell-intrinsic regulation of murine dendritic cell function and survival by prereceptor amplification of glucocorticoidAnnelise Soulier, Sandra M Blois, Shivajanani Sivakumaran, et al.
The Lancet. Oncology|October 3, 2024
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignanciesForam Khatsuria, Christel McMullan, Olalekan Lee Aiyegbusi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 19, 2014
OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescenceSarah Buchan, Teresa Manzo, Barry Flutter, et al.
Blood|April 8, 2010
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioningAdam J Mead, Kirsty J Thomson, Emma C Morris, et al.
Journal of Patient-Reported Outcomes|March 24, 2026
The PRO-CAR-T™ study: achieving excellence in patient and public involvement and engagementKaren L Shaw, Sarah E Hughes, Olalekan L Aiyegbusi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphomaKirsty J Thomson, Emma C Morris, Don Milligan, et al.
The Journal of Experimental Medicine|August 3, 2005
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramersMark Cobbold, Naeem Khan, Batoul Pourgheysari, et al.
The New England Journal of Medicine|July 14, 2021
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host DiseaseRobert Zeiser, Nicola Polverelli, Ron Ram, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 StudyRobert Zeiser, Domenico Russo, Ron Ram, et al.
Pageof 8